NASDAQ (NDAQ) Tops Q1 EPS by 4c

NASDAQ (NASDAQ: NDAQ) reported Q1 EPS of $1.50, $0.04 better than the analyst estimate of $1.46. Revenue for the quarter came in at $701 million versus the consensus estimate of $692.12 million.

“The COVID-19 pandemic’s human, health, societal, and economic costs have been severe and will have lasting implications on our global community,” said Adena Friedman, President and CEO, Nasdaq. “At the same time the crisis has highlighted how humanity manifests itself in inspirational, powerful responses. The unflinching resolve of healthcare and other essential workers, meal delivery efforts and support of small businesses, coupled with the overarching creativity of the human spirit in identifying new ways of working, supporting and caring for each other has been truly awe-inspiring."

Ms. Friedman continued: "I am incredibly proud of the way our Nasdaq team has worked diligently under such unique conditions to sustain uninterrupted access to capital for issuers and investors, as well as supporting our technology clients and their respective economies. Our ability to scale reliably to meet unprecedented trading activity around the world, while effectively serving thousands of clients in our non-trading segments, demonstrates the strength of our business, operating, and financial models. While we continue to evaluate the evolving challenges of the COVID-19 pandemic, we are focused on delivering for all of our stakeholders and investing deliberately and carefully to ensure the company is best positioned to serve our clients’ evolving long-term needs."

GUIDANCE:

The company is updating its 2020 non-GAAP operating expense guidance to the range of $1,320 to $1,370 million, principally to reflect the acquisitions of Solovis and OneReport during the first quarter of 2020. Nasdaq continues to expect its 2020 non-GAAP tax rate to be in the range of 25.5% to 27.5%.

For earnings history and earnings-related data on NASDAQ (NDAQ) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• NVE Corporation names new CEO and expands board to seven members
• Pfizer lung cancer drug misses survival goal in Phase 3 trial